Biotech Firms Partner to Develop AI-Engineered Protein Therapeutics
What happened
Zealand Pharma and Generate Biomedicines entered a collaboration and license agreement to develop protein therapeutics engineered with AI for metabolic diseases. The partnership combines Zealand Pharma’s expertise in metabolic health with Generate Biomedicines’ proprietary generative AI platform. Generate Biomedicines will receive $30 million up-front, up to $35 million in early preclinical milestones, and nearly $1.2 billion in total milestones, plus tiered royalties.
From manilatimes.net
Why it matters
The collaboration is intended to accelerate the design and development of protein therapeutics for obesity and metabolic disease. This agreement expands Zealand Pharma’s capabilities beyond peptides while extending Generate Biomedicines’ platform into obesity and other metabolic diseases.
From manilatimes.net
Who's involved
- DenmarkCountry where the collaboration is taking place
- Oramed PharmaceuticalsPharmaceutical company potentially facing increased competitive pressure
- Novo NordiskDanish pharmaceutical company benefiting from the local ecosystem
- Manufacturers Life Insurance CompanyCompany potentially benefiting from major funding and milestone deals
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Manufacturers Life Insurance CompanySpeculative
Manufacturers Life Insurance Company might benefit from increased valuation due to major funding and milestone deal benefits.
- DenmarkSpeculative
Denmark may see increased national investment confidence and R&D profile validation.